Physician profile
Gillian G Wooldridge
NPI 1053722264
$105,994.99
in general payments reported to CMS, 2019-2025
31 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $341 · 2021: $712 · 2022: $1,257 · 2023: $1,215 · 2024: $21K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Honoraria: $7,395 · Food and Beverage: $6,336 · Consulting Fee: $4,880 · Travel and Lodging: $4,798 · Education: $65.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,730.00 |
| Honoraria | $7,395.00 |
| Food and Beverage | $6,336.30 |
| Consulting Fee | $4,880.00 |
| Travel and Lodging | $4,798.16 |
| Education | $65.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $46,053.32 | 2023-2025 | Crysvita |
| Amgen INC. | $40,310.00 | 2019-2025 | Evenity, Prolia, Prolia |
| Radius Health, INC. | $16,185.35 | 2020-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $1,790.20 | 2022-2025 | Strensiq |
| Pacira Pharmaceuticals Incorporated | $192.82 | 2022-2023 | Iovera, Zilretta, Exparel |
| Novo Nordisk INC | $142.28 | 2019-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $138.25 | 2019-2022 | |
| Medtronic, INC. | $121.59 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $118.98 | 2023 | Seglentis |
| Ascendis Pharma Endocrinology INC | $112.01 | 2025 | Yorvipath |
| Pacira Therapeutics, INC. | $109.37 | 2019 | |
| Ucb, INC. | $89.42 | 2022 | |
| Ferring Pharmaceuticals INC. | $65.98 | 2022-2024 | Euflexxa |
| Pfizer INC. | $63.52 | 2020 | |
| Glaxosmithkline, LLC. | $61.10 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $53.41 | 2019 | |
| Lilly USA, LLC | $51.16 | 2020-2024 | Zepbound |
| Abbvie INC. | $48.23 | 2024 | |
| Alvogen INC | $35.58 | 2025 | Teriparatide |
| Dynavax Technologies Corporation | $35.23 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $30.40 | 2019 | |
| Depuy Synthes Sales INC. | $28.02 | 2019-2025 | Orthovisc, Monovisc |
| Sanofi Pasteur INC. | $26.73 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.17 | 2022 | |
| Merck Sharp & Dohme LLC | $21.66 | 2019 | |
| Bioventus LLC | $17.65 | 2023 | Durolane |
| Takeda Pharmaceuticals U.S.A., INC. | $14.73 | 2020 | |
| Cranial Technologies, INC | $14.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.47 | 2020 | |
| Currax Pharmaceuticals LLC | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gillian Wooldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.